@DrToddLee@ABsteward@BradSpellberg I agree, I think the lack of meropenem activity against enterococcus is a myth. MICs are higher but I think we give enough meropenem for activity. I want to evaluate it in our mouse model with humanized meropenem exposures.
CAIRD at Hartford Hospital (Hartford,CT) is actively recruiting for post-docs (PhD or PharmD) to join our lab! We've been training fellows in ID PK/PD for over 30 years.
Going to ASHP Midyear? Reach out to set up a timeslot in our PPS booth!
Reposts much appreciated! #IDtwitter
https://t.co/n6pHBL1K1K
New pub alert from the lab @hartfordhosp. 🚨💉Relevant study giving SUL-DUR's need to be given in combination for empiric coverage!!💉Take away: Synergy and no antagonism observed
@merwimmer I would reach out to the manufacturer Cipla they should have some options. There was a commercially available assay in development but I think when Achaogen had closed shop it was lost in the shuffle
@Ahsan70000122@RachelCCpharmD There is a multistate outbreak of VIM and GES harboring PSA, if lab can test on carbaR it can pick up the VIM. I would check cefiderocol MIC. Ceftaz/avi+aztreonam is different in PSA vs enterobacterales. The aztreonam-avi MICs are much higher in PSA due to the other mechanisms.
Recall due to VIM-GES-harboring P. aeruginosa contamination which has resulted in infections. Highlights need for carbapenemase-screening strategy in the US for carbapenem-resistant P. aeruginosa.
Global Pharma Healthcare Issues Voluntary Nationwide Recall of Artificial Tears Lubricant Eye Drops Due to Possible Contamination https://t.co/e5xmXv4DP8
The Rhode Island Pharmacy community lost a dear friend, pharmacist, entrepreneur, public service leader and beloved family member earlier this week, Anthony J. Solomon.
🔗Full post: https://t.co/fqYDu79l9Z
🔗Lifetime Achievement Award:
https://t.co/6YtT7wLBBd
1/n
@BWDionne@ErinMcCreary@OncIDPharmd@ryankshields @jpogue1 We’ve seen some unexpectedly low MICs to PipTazo specifically for VIM positive PSA. Like Sam said probably a shortcoming of PipTazo AST rather than true activity but would be interesting to evaluate.
https://t.co/EWVzO4PxzA
@DanyaRoshdy@ryankshields@OncIDPharmd@davidvanduin Some IMPs as well as a number of other MBLs are outside the targets of the CarbaR. A phenotypic carbapenemase test (like the mCIM/eCIM) can detect other non targeted carbapenemases.
@OncIDPharmd@ABsteward@MicrobLog_me_uk@IdVilchez @wfwrighID @a_hamprecht@DrToddLee @Boghuma @transplantID@AntibioticDoc @JGPharmD Have to be aware of the breakpoint differences with meropenem/vaborbactam having higher breakpoints than meropenem alone in context of OXA-48. vaborbactam offering no protection against OXA-48, but more OXA-48 will test S to MVB just due to higher breakpoint
@OncIDPharmd@DrToddLee@sebpoule Would also consider GES-beta-lactamases. have been reported in Canada and I would bet crossing over into US but none of the commercially available platforms can detect https://t.co/my0SrFBSwo